中年人群阿尔茨海默病、脑血管病与血脑屏障通透性生物标志物
研究纳入488名中年参与者(平均年龄54.3岁),分析血脑屏障相关的VEGF家族生物标志物与MRI血管病变及AD血浆标志物的关系。结果显示PlGF与WMH体积、GFAP、p-tau181、NfL正相关,VEGF-D与GFAP、NfL正相关,bFGF与Aβ42/40负相关、与p-tau181正相关。路径分析提示PlGF经WMH间接影响GFAP,进而影响p-tau181和NfL。
要点
- 中年人群血脑屏障通透性标志物与AD病理及脑血管病变相关。
- PlGF升高与WMH体积增大及神经炎症、神经退行标志物升高相关。
- bFGF与Aβ42/40降低和p-tau181升高相关,提示与淀粉样病理关联。
核心结论
- 血脑屏障通透性标志物与中年期AD病理生理、MRI脑血管病变及神经炎症相关。
研究设计与样本
- 研究纳入488名来自AD种族和民族差异后代研究的中年参与者(平均年龄54.3岁,66.8%女性),具有MRI和血浆生物标志物数据。
- 采用Meso Scale Discovery平台检测VEGF-D、PlGF和bFGF浓度,Simoa免疫分析检测Aβ42、Aβ40、p-tau181、GFAP和NfL。
- 从T2加权MRI获取白质高信号体积,进行双变量相关分析和路径分析。
主要发现
- 最佳拟合路径模型显示PlGF对GFAP有间接效应,由WMH介导;GFAP对p-tau181有直接正效应,p-tau181对NfL有正效应;VEGF-D和bFGF对NfL有直接正效应。
临床怎么用
- 在中年人群中,血浆PlGF、VEGF-D和bFGF或可作为反映血脑屏障通透性及相关AD病理的候选生物标志物。
- 血脑屏障通透性标志物可能有助于识别脑血管病变和AD病理早期风险个体。
局限性
- 研究为横断面设计,无法确立因果关系。
- 样本为中年后代研究参与者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cerebrovascular disease (CVD) influences Alzheimer disease (AD) risk and progression, but the link between vascular disease and AD pathophysiology remains unclear, particularly in midlife when the impact of CVD on AD risk may be strongest. This study examined the relationship of recently validated vascular cognitive impairment (VCI) plasma biomarker concentrations that reflect aspects of blood-brain barrier dysfunction with MRI markers of CVD and AD plasma biomarker concentrations. METHODS: The study included middle-aged participants from the Offspring Study of Racial and Ethnic Disparities in AD who had MRI and plasma biomarker data available. Biomarker concentrations of vascular endothelial growth factor (VEGF) family members (VEGF-D, placental growth factor [PlGF], and basic fibroblast growth factor [bFGF]) were measured using the Meso Scale Discovery platform. β-Amyloid (Aβ42, Aβ40), phosphorylated tau 181 (p-tau181), astrocytosis (glial fibrillary acidic protein [GFAP]), and neurodegeneration (neurofilament light chain [NfL]) biomarkers were measured with Simoa immunoassays. White matter hyperintensity (WMH) volumes were derived from T2-weighted MRI scans. Bivariate relationships of WMH, Aβ42/Aβ40 ratio, p-tau181, GFAP, and NfL with VEGF biomarkers were tested, and path analyses examined potential causal pathways linking each VEGF biomarker concentration to WMH and GFAP, as well as their downstream associations with tau pathology and neurodegeneration. RESULTS: We analyzed data from 488 participants (mean [SD] age = 54.3 [10.5]; 66.8% women). Higher PlGF levels were associated with older age (R [CI] = 0.25 [0.17-0.33]); greater WMH volume (R [CI] = 0.2 [0.11-0.29]); and higher levels of GFAP (R [CI] = 0.11 [0.02-0.2]), p-tau181 (R [CI] = 0.12 [0.03-0.21]), and NfL (R [CI] = 0.19 [0.1-0.27]). Higher VEGF-D was associated with increased GFAP (R [CI] = 0.11 [0.02-0.19]) and NfL (R [CI] = 0.16 [0.07-0.25]) levels. bFGF concentration was associated with a lower Aβ42/40 ratio (R [CI] = -0.1 [-0.19 to -0.02]) and higher p-tau181 levels (R [CI] = 0.13 [0.04-0.21]). The best fitting path model showed that PlGF had an indirect effect on GFAP levels mediated by WMH. GFAP subsequently had a direct positive effect on p-tau181, which in turn had a positive effect on NfL levels. VEGF-D and bFGF levels also had a positive direct effect on NfL. DISCUSSION: The findings suggest that permeability of the blood-brain barrier is linked to AD pathophysiology, contributes to cerebrovascular lesions observed on MRI, and is associated with neuroinflammation in middle age.
引用
- Edwards NC, Lao P, Alshikho MJ, et al. Alzheimer Disease, Vascular Disease, and Blood-Brain Barrier Permeability Biomarkers in Middle-Aged Adults. Neurology. 2025. PMID: 41052375. doi:10.1212/WNL.0000000000214220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。